Aevi Genomic Medicine — Q1 2017 Earnings Presentation
29 slides from Aevi Genomic Medicine's earnings presentation, May 10, 2017
Slide 1: Corporate Update May 10, 2017
© 2017, Aevi Genomic Medicine NASDAQ: GNMX Corporate Update May 10, 2017
Slide 2: Forward-Looking Statement
© 2017, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financi
Slide 3: Agenda
© 2017, Aevi Genomic Medicine 3 Agenda • Executive Summary • AEVI - 001 Development Program Update – SAGA trial summary – Genetic Subset Responder Analysis – Addressable Commercial Market – Next Steps for Clinical Development • AEVI - 002 Development Program Update • Q1 17 Results of Operations • Co
Slide 4: Our Mission
© 2017, Aevi Genomic Medicine 4 Our Mission
Slide 5: Aevi Genomic Medicine Pipeline
© 2017, Aevi Genomic Medicine 5 Aevi Genomic Medicine Pipeline Compound Indication Preclinical Phase 1 Phase 2 Phase 3 AEVI - 001 mGluR + Genetic Subset ADHD (pediatric, age 6 - 17) 22q Deletion Syndrome CNTN4 in Autism Spectrum Disorder (Potential Orphan Program) AEVI - 002 (anti - LIGHT mAb) Sever
Slide 6: AEVI-001: SAGA Trial in mGluR+ ADHD
© 2017, Aevi Genomic Medicine AEVI - 001: SAGA Trial in mGluR + ADHD
Slide 7: AEVI-001: ADHD Development Program
© 2017, Aevi Genomic Medicine 7 AEVI - 001: ADHD Development Program Design: • Non - interventional • Multi - center (30+) • Genotype ~1900 ADHD subjects, age 6 - 17, identifying patients who are mGluR+ Objectives: • Confirm prevalence of mGluR+ • Characterize mGluR+ phenotype • Expedite enrollment
Slide 8: SAGA Trial Design in mGluR+ Adolescents
© 2017, Aevi Genomic Medicine 8 Period 1: Double-blind, Dose-Optimization (4 weeks) Screening (up to 3 weeks) Period 2: Double-blind, Dose-Maintenance (2 weeks) Follow-up Call (1 week) Week:-3 0 1 2 3 4 5 6 -2 -1 7 Dose: 100 mg BID, 200 mg BID, 400 mg BID, or placebo Dose optimization based on respo
Slide 9: SAGA Trial Summary
© 2017, Aevi Genomic Medicine 9 SAGA Trial Summary • Trial did not meet primary endpoint (overall ADHD - RS) 1 , however showed encouraging trend in improvement at highest dose (400 mg BID) – Strong trend of efficacy in ADHD - RS inattention subscale (p=0.0515 vs placebo) • Clear signal of efficacy
Slide 10: SAGA Trial Responder Analyses: Patient Stratification by Genetic Biomarkers
© 2017, Aevi Genomic Medicine SAGA Trial Responder Analyses: Patient Stratification by Genetic Biomarkers
Slide 11: Novel-Gene Subset Predictive of Response
© 2017, Aevi Genomic Medicine 11 Novel 9 - Gene Subset Predictive of Response • Emphasis on top 25 genes by frequency of occurrence in phenotype - genotype study • Prioritize genes that have been randomized into both active and placebo arms and showed meaningful response to AEVI - 001 vs placebo • T
Slide 12: Frequency of Responder Genes to AEVI-001
© 2017, Aevi Genomic Medicine 12 C N T N 4 N e u r o G e n e A G R M G e n e A G R M G e n e B N e u r o G e n e B N e u r o G e n e C N e u r o G e n e D N e u r o G e n e E N e u r o G e n e F 0 1 2 3 4 5 P e r c e n t a g e o f T o t a l A D H D Frequency of Responder Genes to AEVI - 001 • 8 of t
Slide 13: Novel Discovery: Prevalence of CNTN4 in ADHD
© 2017, Aevi Genomic Medicine 13 C N T N 4 G e n e 2 4 0 1 2 3 4 5 P e r c e n t a g e o f T o t a l A D H D Novel Discovery: Prevalence of CNTN4 in ADHD • CNTN4 constitutes 22% of the mGluR + population and approximately 5% of the pediatric ADHD population 1 • mGluR mutations were highly concentrat
Slide 14: 9-Gene Subset: Robust Response to AEVI-001
© 2017, Aevi Genomic Medicine 14 9 - Gene Subset: Robust Response to AEVI - 001 B a s e l i n e W e e k 1 ( 1 0 0 m g B I D ) W e e k 2 ( 2 0 0 m g B I D ) W e e k 3 ( 4 0 0 m g B I D ) W e e k 4 ( O p t i m i z e d D o s e ) W e e k 5 ( M a i n t e n a n c e D o s e ) W e e k 6 ( M a i n t e n a n
Slide 15: 9-Gene Subset: Stimulant-like Magnitude of Response
© 2017, Aevi Genomic Medicine 15 9 - Gene Subset: Stimulant - like Magnitude of Response Placebo adjusted change from baseline; adolescent trials Study Medication Change in total ADHD - RS from Baseline Change in Inattention Subscale from Baseline Change in Hyperactivity/Impulsivity Subscale from Ba
Slide 16: 9-Gene Subset: Clinically Meaningful Response Rates
© 2017, Aevi Genomic Medicine 16 0 20 40 60 80 100 P e r c e n t a g e o f p a t i e n t s w h o a c h i e v e d r e s p o n s e AEVI-001 (n=18) Placebo (n=24) 9 - Gene Subset: Clinically Meaningful and Statistically Significant Response Rates, SAGA Trial Week 6 Reduction in ADHD - RS > 30% Week 6 C
Slide 17: CNTN4: Novel Discovery in ADHD
© 2017, Aevi Genomic Medicine 17 CNTN4 : Novel Discovery in ADHD • CNTN4 encodes an axon - associated cell adhesion molecule – Important in neuronal network formation and plasticity • Previously associated with: – Neurodevelopmental delay – Autism Spectrum Disorder (ASD) – Bipolar Disorder – Schizop
Slide 18: CNTN4: More Severe Phenotype
© 2017, Aevi Genomic Medicine 18 Phenotype/Genotype Study (N=1876) • Higher prevalence of emotional dysregulation*: – Disruptive behavior – Completing work – Anger control – Risk taking – Inappropriate movements and sounds – Hyperactivity CNTN4: More Severe Phenotype
Slide 19: CNTN4: Robust Response to AEVI-001
© 2017, Aevi Genomic Medicine 19 B a s e l i n e W e e k 1 ( 1 0 0 m g B I D ) W e e k 2 ( 2 0 0 m g B I D ) W e e k 3 ( 4 0 0 m g B I D ) W e e k 4 ( O p t i m i z e d D o s e ) W e e k 5 ( M a i n t e n a n c e D o s e ) W e e k 6 ( M a i n t e n a n c e D o s e ) -25 -20 -15 -10 -5 0 C h a n g e
Slide 20: 100% Response in CNTN4 Mutation-positive Patients
© 2017, Aevi Genomic Medicine 20 0 20 40 60 80 100 P e r c e n t a g e o f p a t i e n t s w h o a c h i e v e d r e s p o n s e AEVI-001 (n=6) Placebo (n=12) 100% Response in CNTN4 Mutation - positive Patients Week 6 Reduction in ADHD - RS > 30% Week 6 CGI - I of 1 or 2 p = 0.0062 100% 25% 83% 17%
Slide 21: Responder Analysis Summary: ADHD Precision Medicine
© 2017, Aevi Genomic Medicine 21 Responder Analysis Summary: ADHD Precision Medicine • Clinically meaningful and statistically significant response in a 9 - gene responder subpopulation • High magnitude of response: stimulant - like reduction in ADHD - RS • 89% response rates in challenging adolesce
Slide 22: Next Steps for AEVI-001: ADHD and ASD
© 2017, Aevi Genomic Medicine 22 Next Steps for AEVI - 001: ADHD and ASD • Genetic Subset ADHD – Multi - center randomized, placebo - controlled P hase 2 trial in patients ages 6 – 17 – Staged adaptive design – I nitial focus on CNTN4 (n=~ 40 - 70) – Remaining genes to follow – Study start 2H 2017,
Slide 23: ADHD Market Opportunity
© 2017, Aevi Genomic Medicine 23 • Overall US ADHD Market – US market sales: ~$11.1B 1 and growing at ~2 % CAGR 1 – Stimulants dominate market: ~90 % of sales 1 – ~6M pediatric (ages 6 - 17) patients and ~10M adult patients in US 2,3 • 9 - Gene Subset ADHD Market (~10% of ADHD patients) 4 – ~600K pe
Slide 24: AEVI-002: Severe Pediatric Onset Crohn's Disease
© 2017, Aevi Genomic Medicine 24 AEVI - 002: Severe Pediatric Onset Crohn’s Disease
Slide 25: AEVI-002: Anti-LIGHT mAb Program
© 2017, Aevi Genomic Medicine 25 AEVI - 002: Anti - LIGHT mAb Program • First - in - Class Biologic from Kyowa Hakko Kirin – Initial development in Severe Pediatric Onset IBD – Phase 2 ready human monoclonal antibody • Program Update – Successfully transferred IND – Requalified clinical trial materi
Slide 26: Financial Update
© 2017, Aevi Genomic Medicine 26 Financial Update
Slide 27: Q1 Financial Update
© 2017, Aevi Genomic Medicine 27 Q1 17 Financial Update R&D expenses for 1Q 17 were $7.9M, increasing from $7.0M for the same period in 2016 – Mainly due to increased spend on clinical activities related to completion of the SAGA trial for AEVI - 001 & advancement of the AEVI - 002 program G&A expen
Slide 28: Aevi Genomic Medicine – Upcoming Events
© 2017, Aevi Genomic Medicine 28 Aevi Genomic Medicine – Upcoming Events Compound Indication Preclinical Phase 1 Phase 2 Milestones AEVI - 001 mGluR + Genetic Subset ADHD (pediatric, age 6 - 17) 22q Deletion Syndrome CNTN4 in Autism Spectrum Disorder (Potential Orphan Program) AEVI - 002 (anti - LIG
Slide 29: Thank you
© 2017, Aevi Genomic Medicine 29 Thank you
Aevi Genomic Medicine — Q1 2017 Earnings Presentation on 6ix